As the efficacy and safety of PCSK9 inhibitors can continue to be delineated, we can look forward to the evolution of these novel treatments to change the paradigm in the management of ASCVD and better outcomes for patients at high risk for cardiovascular events. The gene discussed is PCSK9; the disease is atherosclerosis.